Metabolic Benefits of TelmisartanMCI Registration NumberFULL NAME (As in your Pancard)EmailPhone/MobileCityStateSpecialityBank DetailsAccount Holder NameA/c NumberIFSC CodeUpload Cancelled Cheque (Max Size - 2 MB)Choose File Pancard NumberUpload Pancard Details (Max Size - 2 MB)Choose File Evaluating Awareness of the Metabolic Benefits of Telmisartan Amongst General Physicians1. Telmisartan's metabolic benefit beyond BP control is primarily attributed to its action on which receptor? PPAR-alpha (full agonist) PPAR-gamma (partial agonist) AT2 receptor upregulation GLP-1 receptor2. Which parameter is most consistently improved by telmisartan independent of its BP-lowering effect? Serum creatinine Insulin sensitivity (HOMA-IR) Bone mineral density Serum uric acid clearance3. Telmisartan's effect on lipid profile is best described as: No significant effect on any lipid parameter Increases LDL, decreases HDL Modest reduction in triglycerides, mild HDL increase Significant reduction in total cholesterol only4. Compared to other ARBs (losartan, valsartan, irbesartan), telmisartan's PPAR-gamma partial agonist activity is: Shared equally across the ARB class A distinguishing pharmacological feature of telmisartan Only seen at supratherapeutic doses in vitro Not clinically relevant at any dose5. Telmisartan has been shown to influence adiponectin levels in which direction? Decrease No effect Increase Effect is sex-dependent only6. In terms of visceral adiposity, telmisartan's evidence base best supports: Significant visceral fat reduction independent of diet No measurable effect on fat distribution Increased visceral fat, similar to thiazolidinediones Effect limited to subcutaneous fat only7. Large outcome trials (ONTARGET/TRANSCEND-derived analyses) on telmisartan and new-onset diabetes suggest: Telmisartan increases new-onset diabetes risk vs placebo No difference vs other ARBs, but favorable trend vs non-ARB comparators Definitive proof of diabetes prevention, statistically powered as primary endpoint Data is inconclusive and contradicts PPAR-gamma mechanism8. For a hypertensive patient with metabolic syndrome, telmisartan's rational positioning versus a metabolically neutral ARB is: No rationale — all ARBs are interchangeable in this population Preferred where metabolic profile improvement is a secondary treatment goal Contraindicated due to weight gain Reserved only for patients already on insulin9. The clinically relevant PPAR-gamma partial (not full) agonism of telmisartan means: Metabolic benefits without the fluid retention/weight gain risk typical of full PPAR-gamma agonists It carries the same edema risk as pioglitazone It requires HbA1c monitoring identical to thiazolidinediones It has no clinical distinction from full agonism10. Self-rated: How confident are you in counseling a patient that telmisartan offers metabolic benefits distinct from other ARBs? Not confident — wasn't aware of this distinction Somewhat aware, but wouldn't cite it clinically Aware and occasionally factor it into ARB choice Aware and actively use it as a differentiator in prescribing decisions I have read and agree to the Terms and Conditions .Submit Form